Carrie L. Bourdow net worth and biography

Carrie Bourdow Biography and Net Worth

Ms. Bourdow was appointed President, Chief Executive Officer, and member of the Trevena Board of Directors in October 2018. She has served in various senior positions at Trevena since May 2015. She joined the Company as Chief Commercial Officer and was appointed Executive Vice President and Chief Operating Officer in January 2018. Prior to joining Trevena, Ms. Bourdow was Vice President of Marketing at Cubist Pharmaceuticals, Inc., from 2013 until its acquisition by Merck & Co. (MRK), Inc. in January 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, reimbursement, and operations for five acute care hospital pharmaceuticals totaling over $1 billion in annual revenues. Prior to Cubist, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across multiple therapeutic areas. Since June 2017, she has served on the board of Nabriva Therapeutics plc. (NBRV), a publicly traded biopharmaceutical company. In February 2020, Ms. Bourdow joined the board of Sesen Bio (SESN), a public biopharmaceutical company.

How old is Carrie L. Bourdow?: Ms. Bourdow is currently 61 years old. There are 4 older executives and no younger executives at Trevena. The oldest executive at Trevena is Dr. Mark A. Demitrack M.D., Senior VP & Chief Medical Officer, who is 66 years old. Learn More on Carrie L. Bourdow's age.
How do I contact Carrie L. Bourdow?: The corporate mailing address for Ms. Bourdow and other Trevena executives is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. Trevena can also be reached via phone at (610) 354-8840 and via email at [email protected]. Learn More on Carrie L. Bourdow's contact information.
Has Carrie L. Bourdow been buying or selling shares of Trevena?: Carrie L. Bourdow has not been actively trading shares of Trevena over the course of the past ninety days. Most recently, on Monday, June 28th, Carrie L. Bourdow bought 2,248 shares of Trevena stock. The stock was acquired at an average cost of $44.75 per share, with a total value of $100,598.00. Learn More on Carrie L. Bourdow's trading history.

Carrie L. Bourdow Insider Trading History at Trevena

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/28/2021	Buy	2,248	$44.75	$100,598.00
11/9/2016	Buy	160	$108.50	$17,360.00

Carrie L. Bourdow Buying and Selling Activity at Trevena

Trevena Company Overview

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Today's Range

Now: $0.37

$0.35

$0.38

50 Day Range

MA: $0.50

$0.35

$0.61

2 Week Range

Now: $0.37

$0.30

$3.28

Volume

81,371 shs

Average Volume

182,477 shs

Market Capitalization

$6.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report